Total | Pre- and postdiagnosis leisure-time physical activity | ||||
---|---|---|---|---|---|
Insufficiently activea | Increasingly active | Decreasingly active | Sufficiently active | ||
n (%) | 2042 (100.0) | 1037 (50.8) | 348 (17.0) | 285 (14.0) | 372 (18.2) |
Age at diagnosis, years, median (IQR)b | 62.9 (58.6–66.4) | 63.4 (59.1–67.1) | 61.9 (58.0–65.3) | 64.1 (59.5–67.1) | 61.1 (57.3–64.4) |
Physical activity prediagnosis, median (IQR) | |||||
Walking (hours/week)b | 6.0 (3.2–9.0) | 6.0 (3.0–9.0) | 6.0 (3.5–9.0) | 7.0 (3.5–10.5) | 6.0 (3.3–9.0) |
Cycling (hours/week)b | 1.2 (0.0–3.5) | 1.0 (0.0–3.5) | 1.4 (0.0–4.0) | 1.8 (0.0–4.0) | 2.0 (0.0–4.0) |
Total (MET-h/week)b | 43.1 (26.5–65.6) | 35.0 (20.0–56.0) | 38.7 (24.2–57.1) | 59.2 (41.1–85.6) | 59.5 (41.7–78.7) |
Physical activity postdiagnosis, median (IQR) | |||||
Walking (hours/week)b | 6.0 (3.0–10.0) | 6.0 (3.0–8.0) | 6.0 (4.0–10.0) | 6.0 (3.0–10.0) | 7.0 (4.0–10.0) |
Cycling (hours/week)b | 1.0 (0.0–3.0) | 0.0 (0.0–2.3) | 2.0 (0.0–4.0) | 1.0 (0.0–3.0) | 2.0 (0.0–3.5) |
Total (MET-h/week)b | 40.0 (23.4–66.0) | 29.6 (16.0–48.0) | 56.6 (37.3–80.1) | 33.1 (17.2–56.0) | 62.2 (40.3–95.6) |
BMI, median (IQR)b | 25.3 (22.9–28.4) | 25.8 (23.3–29.4) | 25.0 (22.8–28.3) | 24.8 (22.9–27.7) | 24.4 (22.5–27.1) |
Smoking status, n (%) | |||||
Never | 1108 (54.3) | 580 (55.9) | 179 (51.4) | 157 (55.1) | 192 (51.6) |
Former | 748 (36.6) | 341 (32.9) | 141 (40.5) | 105 (36.8) | 161 (43.3) |
Current | 186 (9.1) | 116 (11.2) | 28 (8.0) | 23 (8.1) | 19 (5.1) |
Alcohol, g/day, median (IQR)b | 0.7 (0.0–5.7) | 0.6 (0.0–5.4) | 0.7 (0.0–5.7) | 2.0 (0.0–7.1) | 1.4 (0.0–8.3) |
Education, n (%)b | |||||
Less than high/middle school | 1141 (55.9) | 659 (63.5) | 182 (52.3) | 151 (53.0) | 149 (40.1) |
High/middle school | 583 (28.6) | 268 (25.8) | 108 (31.0) | 79 (27.7) | 128 (34.4) |
College or university | 318 (15.6) | 110 (10.6) | 58 (16.7) | 55 (19.3) | 95 (25.5) |
Menopausal hormone use, n (%) | 1000 (49.0) | 483 (46.6) | 171 (49.1) | 150 (52.6) | 196 (52.7) |
Tumour size, cm, n (%) | |||||
< 2 | 1159 (56.8) | 566 (54.6) | 199 (57.2) | 168 (58.9) | 226 (60.8) |
2–5 | 622 (30.5) | 336 (32.4) | 101 (29.0) | 86 (30.2) | 99 (26.6) |
> 5 and growth into chest wall/skin | 73 (3.6) | 46 (4.4) | 11 (3.2) | 8 (2.8) | 8 (2.2) |
Neoadjuvant chemotherapyc | 61 (3.0) | 32 (3.1) | 11 (3.2) | 6 (2.1) | 12 (3.2) |
In situ3 | 124 (6.1) | 54 (5.2) | 26 (7.5) | 17 (6.0) | 27 (7.3) |
Number of positive lymph nodes, n (%) | |||||
0 | 1322 (64.7) | 690 (66.5) | 209 (60.1) | 170 (59.6) | 253 (68.0) |
1–3 | 400 (19.6) | 183 (17.6) | 72 (20.7) | 79 (27.7) | 66 (17.7) |
> 3 | 135 (6.6) | 78 (7.5) | 30 (8.6) | 13 (4.6) | 14 (3.8) |
Tumour grade, n (%) | |||||
Low/moderate | 1422 (69.6) | 720 (69.4) | 240 (69.0) | 197 (69.1) | 265 (71.2) |
High | 426 (20.9) | 223 (21.5) | 71 (20.4) | 64 (22.5) | 68 (18.3) |
Hormone receptor status, n (%) | |||||
ER+/PR+ | 1238 (60.6) | 628 (60.6) | 208 (59.8) | 175 (61.4) | 227 (61.0) |
ER+/PR−, ER−/PR+ | 344 (16.8) | 174 (16.8) | 55 (15.8) | 51 (17.9) | 64 (17.2) |
ER−/PR− | 275 (13.5) | 149 (14.4) | 48 (13.8) | 36 (12.6) | 42 (11.3) |
HER2 status, n (%) | |||||
HER2+ | 312 (15.3) | 159 (15.3) | 63 (18.1) | 46 (16.1) | 44 (11.8) |
HER2− | 1413 (69.2) | 715 (68.9) | 228 (65.5) | 197 (69.1) | 273 (73.4) |
Missing, n (%) | 132 (6.5) | 77 (7.4) | 20 (5.7) | 19 (6.7) | 16 (4.3) |
Type of surgery, n (%) | |||||
Mastectomy | 55 (2.7) | 24 (2.3) | 11 (3.2) | 9 (3.2) | 11 (3.0) |
Mastectomy + axilla | 478 (23.4) | 266 (25.7) | 85 (24.4) | 57 (20.0) | 70 (18.8) |
Breast-conserving therapy | 181 (8.9) | 86 (8.3) | 31 (8.9) | 25 (8.8) | 39 (10.5) |
Breast-conserving therapy + axilla | 1326 (64.9) | 660 (63.6) | 221 (63.5) | 193 (67.7) | 252 (67.7) |
Mode of tumour detection, n (%)b | |||||
Self-detected by palpation/secretion/pain | 1007 (49.3) | 550 (53.0) | 151 (43.4) | 136 (47.7) | 170 (45.7) |
Routine examination, mammography, ultrasound | 1031 (50.5) | 485 (46.8) | 195 (56.0) | 149 (52.3) | 202 (54.3) |
Chemotherapy, n (%) | 917 (44.9) | 481 (46.4) | 163 (46.8) | 127 (44.6) | 146 (39.2) |
Radiation therapy, n (%) | 1627 (79.7) | 828 (79.8) | 274 (78.7) | 230 (80.7) | 295 (79.3) |
Hormone therapy, n (%) | 1651 (80.9) | 842 (81.2) | 276 (79.3) | 228 (80.0) | 305 (82.0) |
Diabetes, n (%)b | 239 (11.7) | 162 (15.6) | 21 (6.0) | 32 (11.2) | 24 (6.5) |
Cardiovascular disease, n (%)b | 1349 (66.1) | 737 (71.1) | 227 (65.2) | 180 (63.2) | 205 (55.1) |
Osteoporosis, n (%) | 452 (22.1) | 241 (23.2) | 74 (21.3) | 69 (24.2) | 68 (18.3) |